Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Intravenous Esketamine for Prevention of Postoperative Delirium
ChiCTR2500109383Phase 3Recruiting
- Sponsor
- People's Hospital of Xinjiang Uygur Autonomous Region
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative delirium (POD) comparing Esketamine 0.25 mg/kg/h with Placebo (2 arms). Primary endpoint: Incidence of postoperative delirium. Started Sep 2025; status: recruiting.
02
Drugs
esketamine
03
Conditions
postoperative delirium (POD)
Beyond the preview
Go deeper on ChiCTR2500109383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109383.